Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

ADC Therapeutics SA

ADCTNYSEEQUITYCurrent

Beneficial Ownership Report

Filed Oct 29, 2026Accepted Oct 29, 2026, 5:45 PM EDTFiling CIK 2015553Accession 0001193125-26-438199
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
ADC Therapeutics SA
Company CIK
0001771910
Street
Route de la Corniche 3B
Street (continued)
1066 Epalinges
City
Switzerland
State / country code
V8
Postal code
0000

Statement details

Security class
Common Shares, par value CHF 0.08 per share
Event date
10/22/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
Bain Capital Life Sciences Opportunities IV, L.P.
Citizenship / organization
DE
Reporting person type
PN
Aggregate amount owned
14,825,625
Percent of class
9.99
Sole voting power
0
Shared voting power
14,825,625
Sole dispositive power
0
Shared dispositive power
14,825,625
Aggregate excludes certain shares
N

Item 1

Issuer

ADC Therapeutics SA

Principal executive office address

Route de la Corniche 3B, 1066 Epalinges, Switzerland.

Item 2

Citizenship

Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware.

Filing person

This Schedule 13G is being filed by Bain Capital Life Sciences Opportunities IV, L.P., a Delaware limited partnership (the "Reporting Person"). Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company ("BCLSI"), is the manager of Bain Capital Life Sciences IV General Partner, LLC, a Delaware limited liability company ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P., a Delaware limited partnership ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund IV GP and BCLS Fund IV, the "Bain Capital Life Sciences Entities"), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.

Principal business or residence address

The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.

Item 3

Not applicable indication

Y

Item 4

Percent of class

See Item 4(a) hereof.

Amount beneficially owned

As of October 22, 2026, the Reporting Person held 7,000,000 Common Shares and pre-funded warrants to purchase up to 22,703,927 Common Shares. The Reporting Person is prohibited from exercising the pre-funded warrants if, as a result of such exercise, the Reporting Person would beneficially own more than 9.99% of the total number of Common Shares then issued and outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Blocker"). Accordingly, pursuant to Rule 13d-3 of the Act, the Reporting Person may be deemed to beneficially own 9.99% of the outstanding Common Shares, representing 14,825,625 Common Shares as of October 22, 2026. The percentage of the outstanding Common Shares held by the Reporting Person is based on (i) 127,667,695 Common Shares outstanding as of August 3, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 13, 2026, (ii) 12,911,347 Common Shares sold by the Issuer in a private placement on October 22, 2026, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on October 13, 2026, and (iii) 7,825,625 Common Shares issuable upon the partial exercise of the pre-funded warrants held by the Reporting Person, which reflects the Beneficial Ownership Blocker.

Sole voting power

0

Shared voting power

See Item 4(a) hereof.

Sole dispositive power

0

Shared dispositive power

See Item 4(a) hereof.

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature comments

Bain Capital Life Sciences Investors, LLC is the manager of Bain Capital Life Sciences IV General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund IV, L.P., which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC, which is the general partner of the Reporting Person.

Signature 1

Reporting person
Bain Capital Life Sciences Opportunities IV, L.P.
Signed
/s/ Andrew Hack
Title
Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC
Date
10/29/2026

Company context

Current securities

Recent company filings

  1. EFFECT filingNov 19, 2026
  2. 424B3 filingNov 19, 2026
  3. SCHEDULE 13G/A - filed by Prosight Management, LP regarding ADC Therapeutics SANov 13, 2026
  4. S-3 filingNov 10, 2026
  5. 10-Q filingNov 9, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.